Cilostazol, a specific PDE-3 inhibitor, ameliorates chronic ileitis via suppression of interaction of platelets with monocytes

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 297, Issue 6, 2009, Pages

  Matsunaga, Hisayuki ^a   Hokari, Ryota ^a   Higashiyama, Masaaki ^a   Kurihara, Chie ^a   Okada, Yoshikiyo ^a   Watanabe, Chikako ^a   Komoto, Shunsuke ^a   Nakamura, Mitsuyasu ^a   Kawaguchi, Atsushi ^a   Nagao, Shigeaki ^a   Miura, Soichiro ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Ileum; Inflammation; Mice; Recruitment

Indexed keywords

CILOSTAZOL; PHOSPHODIESTERASE III INHIBITOR; PIROXICAM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CELL INTERACTION; CELL INVASION; CELL MIGRATION; CHRONIC DISEASE; CONTROLLED STUDY; CROHN DISEASE; FLUORESCENCE MICROSCOPE; HISTOLOGY; HISTOPATHOLOGY; ILEITIS; ILEUM MUCOSA; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; INFLAMMATORY CELL; MACROPHAGE; MICROVASCULATURE; MONOCYTE; MOUSE; MOUSE STRAIN; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; SENESCENCE ACCELERATED MOUSE; THROMBOCYTE; THROMBOCYTE AGGREGATION INHIBITION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BLOOD PLATELETS; CELL MOVEMENT; CHRONIC DISEASE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; DISEASE MODELS, ANIMAL; GASTROINTESTINAL AGENTS; ILEITIS; ILEUM; MICE; MONOCYTES; P-SELECTIN; PHOSPHODIESTERASE INHIBITORS; PIROXICAM; PLATELET AGGREGATION INHIBITORS; TETRAZOLES; TIME FACTORS; VENULES;

EID: 72749118758     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00240.2009     Document Type: Article

References (44)

1. Berg DJ, Zhang J, Weinstock JV, Ismail HF, Earle KA, Alila H, Pamukcu R, Moore S, Lynch RG. Rapid development of colitis in NSAID-treated IL-10-deficient mice. Gastroenterology 123: 1527-1542, 2002. (Pubitemid 35231653)
2. Boswell-Smith V, Cazzola M, Page CP. Are phosphodiesterase 4 inhibitors just more theophylline. J Allergy Clin Immunol 117: 1237-1243, 2006. (Pubitemid 43795733)
3. Brindis RG, Kloner RA. Sildenafil in patients with cardiovascular disease. Am J Cardiol 92: 26M-36M, 2003.
4. Burgio VL, Fais S, Boirivant M, Perrone A, Pallone F. Peripheral monocyte and naive T-cell recruitment and activation in Crohn's disease. Gastroenterology 109: 1029-1038, 1995.
5. Clifford DB. Natalizumab and PML: a risky business. Gut 57: 1347-1349, 2008.
6. Collins CE, Cahill MR, Newland AC, Rampton DS. Platelets circulate in an activated state in inflammatory bowel disease. Gastroenterology 106: 840-845, 1994. (Pubitemid 24109268)
7. Danese S, Katz JA, Saibeni S, Papa A, Gasbarrini A, Vecchi M, Fiocchi C. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut 52: 1435-1441, 2003. (Pubitemid 37176723)
8. Danese S, de la Motte C, Fiocchi C. Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications. Am J Gastroenterol 99: 938-945, 2004. (Pubitemid 39090227)
9. Danese S, de la Motte C, Sturm A, Vogel JD, West GA, Strong SA, Katz JA, Fiocchi C. Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients. Gastroenterology 124: 1249-1264, 2003. (Pubitemid 36531801)
10. Dinter H, Tse J, Halks-Miller M, Asarnow D, Onuffer J, Faulds D, Mitrovic B, Kirsch G, Laurent H, Esperling P, Seidelmann D, Ottow E, Schneider H, Tuohy VK, Wachtel H, Perez HD. The type IV phosphodiesterase specific inhibitor mesopram inhibits experimental autoimmune encephalomyelitis in rodents. J Neuroimmunol 108: 136-146, 2000. (Pubitemid 30438761)
11. Fujita K, Nozaki Y, Wada K, Yoneda M, Endo H, Takahashi H, Iwasaki T, Inamori M, Abe Y, Kobayashi N, Kirikoshi H, Kubota K, Saito S, Nagashima Y, Nakajima A. Effectiveness of antiplatelet drugs against experimental nonalcoholic fatty liver disease. Gut 57: 1583-1591, 2008.
12. Fukunaga K, Fukuda Y, Yokoyama Y, Ohnishi K, Kusaka T, Kosaka T, Hida N, Ohda Y, Miwa H, Matsumoto T. Activated platelets as a possible early marker to predict clinical efficacy of leukocytapheresis in severe ulcerative colitis patients. J Gastroenterol 41: 524-532, 2006. (Pubitemid 44138193)
13. Furie B, Furie BC. The molecular basis of platelet and endothelial cell interaction with neutrophils and monocytes: role of P-selectin and the P-selectin ligand, PSGL-1. Thromb Haemost 74: 224-227, 1995.
14. Grimm MC, Pullman WE, Bennett GM, Sullivan PJ, Pavli P, Doe WF. Direct evidence of monocyte recruitment to inflammatory bowel disease mucosa. J Gastroenterol Hepatol 10: 387-395, 1995.
15. Higashiyama M, Hokari R, Matsunaga H, Takebayashi K, Watanabe C, Komoto S, Okada Y, Kurihara C, Kawaguchi A, Nagao S, Itoh K, Miura S. P-selectin-dependent monocyte recruitment through platelet interaction in intestinal microvessels of LPS-treated mice. Microcirculation 15: 441-450, 2008. (Pubitemid 351934067)
16. Iba T, Kidokoro A, Fukunaga M, Takuhiro K, Ouchi M, Ito Y. Comparison of the protective effects of type III phosphodiesterase (PDE3) inhibitor (cilostazol) and acetylsalicylic acid on intestinal microcirculation after ischemia reperfusion injury in mice. Shock 26: 522-526, 2006. (Pubitemid 44632284)
17. + monocytic cell recruitment in intestinal mucosa and ameliorates ileitis in SAMP1/Yit mice. J Leukoc Biol 77: 287-295, 2005.
18. Ishii N, Tsuzuki Y, Matsuzaki K, Miyazaki J, Okada Y, Hokari R, Kawaguchi A, Nagao S, Itoh K, Miura S. Endotoxin stimulates monocyte-endothelial cell interactions in mouse intestinal Peyer's patches and villus mucosa. Clin Exp Immunol 135: 226-232, 2004. (Pubitemid 38177960)
19. Ishikawa M, Cooper D, Russell J, Salter JW, Zhang JH, Nanda A, Granger DN. Molecular determinants of the prothrombogenic and inflammatory phenotype assumed by the postischemic cerebral microcirculation. Stroke 34: 1777-1782, 2003. (Pubitemid 36842645)
20. Ito H, Miyakoda G, Mori T. Cilostazol inhibits platelet-leukocyte interaction by suppression of platelet activation. Platelets 15: 293-301, 2004. (Pubitemid 39037131)
21. Kamada N, Hisamatsu T, Okamoto S, Chinen H, Kobayashi T, Sato T, Sakuraba A, Kitazume MT, Sugita A, Koganei K, Akagawa KS, Hibi T. Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-gamma axis. J Clin Invest 118: 2269-2280, 2008. (Pubitemid 351872344)
22. Kariyazono H, Nakamura K, Shinkawa T, Yamaguchi T, Sakata R, Yamada K. Inhibition of platelet aggregation and the release of P-selectin from platelets by cilostazol. Thromb Res 101: 445-453, 2001. (Pubitemid 32367921)
23. Lee JH, Oh GT, Park SY, Choi JH, Park JG, Kim CD, Lee WS, Rhim BY, Shin YW, Hong KW. Cilostazol reduces atherosclerosis by inhibition of superoxide and tumor necrosis factor-alpha formation in low-density lipoprotein receptor-null mice fed high cholesterol. J Pharmacol Exp Ther 313: 502-509, 2005.
24. Liu Z, Colpaert S, D'Haens GR, Kasran A, de Boer M, Rutgeerts P, Geboes K, Ceuppens JL. Hyperexpression of CD40 ligand (CD154) in inflammatory bowel disease and its contribution to pathogenic cytokine production. J Immunol 163: 4049-4057, 1999. (Pubitemid 29450936)
25. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 109: 366-398, 2006. (Pubitemid 43132818)
26. Mahida YR. The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflamm Bowel Dis 6: 21-33, 2000.
27. Massberg S, Brand K, Grüner S, Page S, Müller E, Müller I, Bergmeier W, Richter T, Lorenz M, Konrad I, Nieswandt B, Gawaz M. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 196: 887-896, 2002.
28. Matsuzaki K, Tsuzuki Y, Matsunaga H, Inoue T, Miyazaki J, Hokari R, Okada Y, Kawaguchi A, Nagao S, Itoh K, Matsumoto S, Miura S. In vivo demonstration of T lymphocyte migration and amelioration of ileitis in intestinal mucosa of SAMP1/Yit mice by the inhibition of MAdCAM-1. Clin Exp Immunol 140: 22-31, 2005. (Pubitemid 40461069)
29. McEver RP. Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. Thromb Haemost 86: 746-756, 2001.
30. Moore KL, Patel KD, Bruehl RE, Li F, Johnson DA, Lichenstein HS, Cummings RD, Bainton DF, McEver RP. P-selectin glycoprotein ligand- 1 mediates rolling of human neutrophils on P-selectin. J Cell Biol 128: 661-671, 1995.
31. Nishiyori A, Nagakura Y, Ichikawa K. Piroxicam accelerates development of colitis in T-cell receptor alpha chain-deficient mice. Eur J Pharmacol 615: 241-245, 2009.
32. Odashima M, Otaka M, Ohba R, Jin M, Wada I, Horikawa Y, Matsuhashi T, Hatakeyama N, Oyake J, Watanabe S. Attenuation of gastric mucosal inflammation induced by aspirin through inhibition of selective type III phosphodiesterase in rats. Dig Dis Sci 52: 1355-1359, 2007. (Pubitemid 46626186)
33. Ohba R, Otaka M, Odashima M, Jin M, Komatsu K, Konishi N, Wada I, Horikawa Y, Matsuhashi T, Oyake J, Hatakeyama N, Watanabe S. Effect of cilostazol, a selective type-III phosphodiesterase inhibitor, on water-immersion stress-induced gastric mucosal injury in rats. J Gastroenterol 41: 34-40, 2006. (Pubitemid 43299873)
34. Rosh JR, Gross T, Mamula P, Griffiths A, Hyams J. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm Bowel Dis 13: 1024-1030, 2007. (Pubitemid 47309975)
35. Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology 122: 1592-1608, 2002. (Pubitemid 34533555)
36. Sanz MJ, Alvarez A, Piqueras L, Cerda M, Issekutz AC, Lobb RR, Cortijo J, Morcillo EJ. Rolipram inhibits leukocyte-endothelial cell interactions in vivo through P- and E-selectin downregulation. Br J Pharmacol 135: 1872-1881, 2002.
37. Schmidt W, Tinelli M, Secchi A, Gebhard MM, Martin E, Schmidt H. Influence of amrinone on intestinal villus blood flow during endotoxemia. J Crit Care 15: 97-102, 2000. (Pubitemid 32103683)
38. Seizer P, Gawaz M, May AE. Platelet-monocyte interactions - a dangerous liaison linking thrombosis, inflammation and atherosclerosis. Curr Med Chem 15: 1976-1980, 2008.
39. Sudo T, Tachibana K, Toga K, Tochizawa S, Inoue Y, Kimura Y, Hidaka H. Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. Biochem Pharmacol 59: 347-356, 2000. (Pubitemid 30015963)
40. Suzuki K, Sugimura K, Hasegawa K, Yoshida K, Suzuki A, Ishizuka K, Ohtsuka K, Honma T, Narisawa R, Asakura H. Activated platelets in ulcerative colitis enhance the production of reactive oxygen species by polymorphonuclear leukocytes. Scand J Gastroenterol 36: 1301-1306, 2001. (Pubitemid 33027810)
41. Tailor A, Granger DN. Hypercholesterolemia promotes P-selectin-dependent platelet-endothelial cell adhesion in postcapillary venules. Arterioscler Thromb Vasc Biol 23: 675-680, 2003. (Pubitemid 36438083)
42. Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, Spehlmann ME, Rutgeerts PJ, Tulassay Z, Volfova M, Wolf DC, Hernandez C, Bornstein J, Sandborn WJ; International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 132: 1672-1683, 2007.
43. Tohma T, Shimabukuro M, Oshiro Y, Yamakawa M, Shimajiri Y, Takasu N. Cilostazol, a phosphodiesterase inhibitor, reduces microalbuminuria in the insulin-resistant Otsuka Long-Evans Tokushima Fatty rat. Metabolism 53: 1405-1410, 2004. (Pubitemid 39410378)
44. Wang F, Li M, Cheng L, Zhang T, Hu J, Cao M, Zhao J, Guo R, Gao L, Zhang X. Intervention with cilostazol attenuates renal inflammation in streptozotocin-induced diabetic rats. Life Sci 83: 828-835, 2008.